Hepatocellular carcinoma treatment response: Imaging findings and criteria

Table 2 Differences between Response Evaluation Criteria in Solid Tumors 1.1, Modified Response Evaluation Criteria in Solid Tumors, and LR-TRA

	RECIST 1.1	mRECIST	LR-TRA
Evaluation targets	Largest diameter of target lesions	Largest diameter of the viable portion of target lesions	Mass-like enhancement; Ancillary Li-RADS features
Advantages	-	Evaluation of post-treatment changes in lesion vascularity	Response to therapy is evaluated at a lesion-level; Pseudoprogression is not taken into account; Evaluation of response to radiotherapies
Limits	Post-treatment changes in lesion vascularity are not evaluated; Evaluation of response to immunotherapies	Evaluation of response to immunotherapies	Evaluation of response to systemic or immunotherapy; Hepatobiliary phase is not an ancillary feature

RECIST 1.1: Response Evaluation Criteria in Solid Tumors 1.1; mRECIST: Modified Response Evaluation Criteria in Solid Tumors; LR-TRA: LI-RADS Treatment Response.